FibroGen ROCE 2024

Ką veikia FibroGen?

FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.